Atlas Trials

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Clinical trial NCT03170180 · COMPLETED

Trial details

NCT number
NCT03170180
Sponsor
Samsung Medical Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Stomach Neoplasms
Start date
2017-03-01
Primary completion
2021-10-31
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.